(NYSE: ABBV) Abbvie's forecast annual revenue growth rate of 6.93% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 9.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.21%.
Abbvie's revenue in 2025 is $56,334,000,000.On average, 7 Wall Street analysts forecast ABBV's revenue for 2025 to be $105,187,862,506,344, with the lowest ABBV revenue forecast at $104,271,479,156,522, and the highest ABBV revenue forecast at $106,896,402,949,917. On average, 7 Wall Street analysts forecast ABBV's revenue for 2026 to be $113,434,085,733,123, with the lowest ABBV revenue forecast at $111,618,091,669,993, and the highest ABBV revenue forecast at $117,612,980,794,702.
In 2027, ABBV is forecast to generate $121,562,033,715,059 in revenue, with the lowest revenue forecast at $118,353,264,701,276 and the highest revenue forecast at $126,040,232,335,498.